Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial
- Eylea found no more effective than Lucentis after two years
- `Not going to change my treatment approach,' study leader says
This article is for subscribers only.
Regeneron Pharmaceuticals Inc.’s Eylea injection was no more effective in treating a severe eye disease than Roche Holding AG’s Lucentis after two years, according to findings from a new study that may not be enough to knock Regeneron off its dominant perch in the field.
The study is an update from one published last year, which found Eylea was more effective than Lucentis or another Roche drug, Avastin, in patients with moderate to severe visual impairment due to diabetic macular edema. Regeneron trumpeted those results and attributed its increasing share of the market in part to doctors’ enthusiasm over them.